Related Experiment Videos
Cell cycle checkpoints as therapeutic targets.
1Department of Biochemistry, Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Journal of Mammary Gland Biology and Neoplasia
|March 8, 2000
Summary
Most human breast tumors develop from genetic changes that compromise DNA repair and cell cycle checkpoints. Understanding these mutations in breast cancer offers potential for new chemotherapy strategies targeting cell cycle control.
Area of Science:
- Molecular biology
- Genetics
- Oncology
Background:
- Human breast tumors originate from accumulated genetic alterations.
- Genomic instability, driven by errors in DNA replication, repair, and division, is central to breast cancer progression.
- Cell cycle checkpoints are crucial for maintaining genomic integrity by halting cell division in response to DNA damage.
Purpose of the Study:
- To review cell cycle checkpoint signaling pathways frequently altered in human breast tumors.
- To explore the therapeutic potential of targeting these checkpoint pathways for cancer treatment.
Main Methods:
- Literature review of cell cycle checkpoint pathways.
- Analysis of common mutations in human breast tumors affecting these pathways.
- Identification of potential therapeutic targets within checkpoint signaling.
Main Results:
- Specific cell cycle checkpoint pathways are recurrently mutated in breast cancer.
- These mutations disrupt normal cell cycle control, promoting tumor growth and invasiveness.
- Components of these pathways represent viable targets for novel chemotherapeutic agents.
Conclusions:
- Dysregulation of cell cycle checkpoints is a hallmark of human breast cancer.
- Targeting these aberrant pathways holds promise for developing effective breast cancer therapies.